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Abstract
Computer modeling of natural products (NPs) and NP scaffolds is increasingly gaining 
importance in drug discovery, particularly in hit/lead discovery programs and at the 
lead optimization stage. Even though industry had lost interest in the implication of NPs 
in hit/lead searches, recent reports still show that computer modeling could be a use-
ful assert for the identification of starting scaffolds from nature, which could be further 
exploited by synthetic modifications. In this chapter, the focus is on some useful tools for 
computer modeling aimed at the discovery of anticancer drugs from NP scaffolds. We 
also focus on some recent developments toward the identification of potential anticancer 
agents by the application of computer modeling. The chapter will lay emphasis on natu-
ral sources of anticancer compounds, present some useful databases and computational 
tools for anticancer drug discovery, and show some recent case studies of the application 
of computational modeling in anticancer drug discovery, as well as some success stories 
in virtual screening applications in anticancer drug discovery, highlighting some use-
ful results on the application of on lead discovery (including promising NP scaffolds) 
against an interesting anticancer drug target, the protein kinase C-related kinase (PRK1).
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1. Introduction
1.1. Cancer and natural products
Cancer is one of the most feared causes of death, as it represents several disease forms and 
treatments possibilities are still limited for late stages of the disease [1]. Among the known 
drugs for cancer treatment, camptothecin, vinblastine, vincristine, podophyllotoxin, and taxol 
are of natural origin [2]. Nature is known to be an immense repository of natural products 
(NPs), constituting the source of about half of the anticancer drugs currently in the market [3]. 
Inspite of the drop in interest for NPs in drug discovery projects, from an industrial point of 
view, recent reports still show that NPs could constitute a useful assert for the identification of 
starting scaffolds for further discovery [4–6]. The quest for anticancer drugs of natural origin 
or with NP scaffolds has resulted in the development of NP databases, the most promising 
one being the naturally occurring plant-based anti-cancer compound activity-target database 
(NPACT), with ~1500 NPs, including experimentally verified in vitro and in vivo biological 
activities (in the form of IC50s, ED50s, EC50s, GI50s, etc.), along with physical, elemental, and topological properties of the compounds, the tested cancer types, cell lines, protein targets, 
commercial suppliers, and drug-likeness classification for each compound [7].
1.2. Prostate cancer
Among the many diverse cancer forms, prostate cancer is the second leading cause of cancer 
deaths in men worldwide [8]. Two different types of prostate cancer were identified: andro-
gen-dependent prostate cancer and androgen-independent prostate cancer [9]. Androgen 
hormones (testosterone or dihydrotestosterone) are known to activate the androgen receptors 
located in the cell nucleus. The main function of these receptors is to modify gene expressions, 
thus controlling several biological activities in the cells, including cell growth and differentia-
tion, development, and function of male reproductive and accessory sex tissues [10, 11]. It was 
found that the androgen receptors signaling pathway plays an important role in the prog-
ress and development of prostate cancer. In the first stage of androgen-dependent prostate 
cancer, the survival and growth of the cancer cells are mainly dependent on androgen hor-
mones [11]. The initial treatment of androgen-dependent cancer, based on androgen ablation, 
is called hormone therapy. This procedure aims to stop the cell growth of cancer cells, which, 
in most cases, respond to this therapy. The recurring prostate cancer cells from hormone 
therapy would further not respond to androgen ablation, thus leading to the development 
of androgen-independent prostate cancer, which can further progress to metastasis [11]. The 
molecular mechanism of tumor recurrence is not completely clear. For the second stage of 
prostate cancer, there is no efficient therapy available.
1.3. Protein kinase C–related kinase
Protein kinase C–related kinase (PRK1, also known as PKN1) is a serine/threonine kinase 
known to play a role in controlling the activity of androgen receptors in prostate cancer. 
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It was shown that the activation of PRK1 stimulates the activity of androgen receptors and 
is involved in tumorigenesis [12]. In 2008, Schüle et al. showed that PRK1 phosphorylates 
histone H3 upon ligand-dependent recruitment to androgen receptor target genes [12]. The 
phosphorylation of histone H3 at threonine 11 (H3T11) increases demethylation of Lys-9 
by Jumonji C (JmjC)-domain-containing protein (JMJD2C), which promotes androgen 
receptor-dependent gene expression and tumor cell proliferation [13]. Additionally, PRK1 
may directly phosphorylate JMJD2C, thereby stimulating its activity [14]. Meanwhile, the 
role of PRK1 in androgen-independent prostate cancer is unknown. PRK1 can be activated 
by the Rho family GTPases, thus mediating several processes related to the migration and 
cancer cell invasion and consequently playing a major role in the formation of metastases 
[15, 16]. Thus, PRK1 is considered to be a promising therapeutic target, and the discovery 
of novel potent and selective inhibitors could supply a meaningful tool for the treatment of 
prostate cancer. On the other hand, the discovery of selective and potent inhibitors would 
provide a tool for understanding particular biological roles of PRK1. In spite of the impor-
tance of PRK1 in the targeted therapy of cancer, only a few known inhibitors have been 
identified. The known PKC inhibitors (Figures 1 and 2) include staurosporine (PubChem 
CID: 44259) and its analogue (Ro-318220; PubChem CID: 5083), bisindolylmaleimide I (BIM 
I; PubChem CID: 2396), and lestaurtinib (PubChem CID: 126565), as well as the nonselective 
Akt inhibitor GSK-690693 (PubChem CID: 16725726) and Pfizer’s JAK nonselective inhibitor 
CP-690550 (tofacitinib; PubChem CID: 9926791) [17, 18]. In a previous work, several novel 
PRK1 inhibitors were identified containing different scaffolds, using a homology model, 
with varying potencies [19]. In the present work, the focus is to search for new small mol-
ecules and natural products, which could inhibit PRK1 by using the recently published 
crystal structures.
1.4. Structural analysis of PRK1
PRK1 kinase belongs to the protein kinase C (PKC) superfamily and was first identified in 
1994 from a human hippocampal cDNA library [20]. Three isoforms are found in mammals 
(called PRK1, PRK2, and PRK3). They possess different enzymatic properties and are distrib-
uted among different tissues [21]. The PRK1 structure is divided into three conserved regions:
• an N-terminal lobe (which includes a regulatory region containing three homologous 
stretches and is rich in charged amino acids),
• an auto-inhibitory domain called C2-like region (which is sensitive to arachidonic acids), and
• a C-terminal lobe (which contains the catalytic domains or called kinase domain).
Both lobes are connected by a hinge region. The catalytic domain is located between both 
terminal lobes and shows high conservation and similarity to the PKC family kinase domain 
[21, 22]. Moreover, PRK1 and PKC are members of AGC kinase family [23]. The characteris-
tic feature of these kinases is a C-terminal regulatory region (C-tail). The C-tails regulate the 
enzymatic activity and insert conserved phenylalanine residues into the ATP-binding site 
[23–25].
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1.5. Computational approaches in drug discovery
Virtual screening (VS) was first used at the end of the last century to refer to computational 
algorithms and techniques used to identify novel hit/lead compounds for biological target 
Figure 1. Chemical structures of PRK1 active compounds: (A) staurosporine and derivatives, (B) tofacitinib and other 
pyrrolopyrimidine derivatives [18].
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from large chemical libraries, depending on the known structure or the drug target or active 
ligands [26–29]. The VS approach is considered as a complementary approach to experimen-
tal or physical screening or high-throughput screening (HTS). VS has been fully integrated 
to most modern day drug discovery projects [30]. However, VS does not require the physical 
existence of the compounds to be tested. It is only based on computer models or the three-
dimensional (3D) structures of the drug target, also known as structure-based VS (SBVS) or on 
the chemical structure of known active ligand(s), also known as ligand-based VS (LBVS) [31]. 
The fundamentals of the SBVS approach depend on the availability of the 3D structure of the 
biological target and a database of small molecules. The SBVS approach often uses molecular 
docking to generate the protein-ligand complexes of small molecules from a database into 
the target active site. The aim is to identify the compounds, which interact favorably with 
the target binding site [32]. Meanwhile, LBVS methods utilize chemical similarity analysis of 
structurally diverse or known active ligands, with the view of identifying novel small mole-
cules, which could show similar biological activities [33–35]. However, both approaches have 
practical limitations. Therefore, researchers often combine SBVS and LBVS, with the aim that 
this might improve the efficiency of the VS results [36, 37]. Computational approaches for 
the prediction of biological activity also include quantitative structure-activity relationships 
(QSAR) analysis, which is aimed at finding a correlation between predicted and experimen-
tal biological activities of small molecules. This approach incorporates the influence of the 
molecular descriptors. QSAR models can be used initially to predict the activity of untested 
hits from a virtual screening campaign [38]. On other hand, QSAR modeling is useful tool 
during lead optimization, which is aimed at the improvement of the biological activities of 
the identified hits [39]. Recently, many crystal structures of the PRK1 drug target have been 
published [24]. Due to the flexibility of the biding site of the PRK1 structure, which adapts to 
different conformations, each protein-ligand complex was individually analyzed to reveal the 
important intermolecular interactions responsible for ligand binding that are useful for the 
Figure 2. Chemical structures of more PRK1 active compounds. (A) Isoquinoline derivatives, (B) PD-0166285 and 
structurally diverse compounds identified by VS [18].
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identification new hits. The aim of this research project is to analyze ligand binding to PRK1 
and to identify novel-specific inhibitors that could block the activity of PRK1, using structure-
based VS. In a preliminary study, the applied docking methods were validated and used to 
investigate its ability to predict the experimental conformations of the co-crystallized ligands. 
Second, several QSAR models were generated in order to find the significant correlations 
between the computational and experimental biological activity data. The constructed QSAR 
models contain different scoring functions, including computed binding-free energy (BFE) 
values for the protein-ligand complexes, in addition to molecular descriptors of the isolated 
ligands. To investigate the predictive ability of the generated QSAR models, internal and 
external methods were performed. Moreover, an enrichment study was performed, in order 
to assess the ability of the scoring functions to identify known binders or actives in large data-
bases containing actives and inactives. By focusing on kinase data sets, GSK data sets 1 and 2 
were screened to search for novel lead compounds, employing virtual screening methods. A 
NP library including compounds isolated from African flora was also screened. This chapter 
begins by presenting database tools (small molecule libraries) useful in VS campaigns, with 
a focus on small molecule libraries and NPs with anticancer properties. This is followed by 
some recent success stories on VS for the identification of inhibitors and/or modulators of 
some anticancer drug targets. The end of the chapter shows the case study of VS for the iden-
tification of PRK1 inhibitors.
2. Databases of small molecule libraries and some recent success stories 
in anticancer drug discovery using computer-based methods
2.1. Small molecule databases for virtual screening
A summary of small molecule libraries utilizable in virtual screening experiments has been 
provided in Table 1. Known cancer drugs have been included in several databases, including 
ChEBI [43], ChEMBL [44], DrugBank [46], EpiDBase [48], NANPDB [51], NCI-DIS, NCI-DTP, 
and NCI-FDA [52], along with SANCDB [54], SuperDrug [55], p-ANAPL [58], PubChem [59], 
and ZINC15 [60]. However, those with tested and proven in vitro activities against known 
cancer cell lines and/or with known in vivo activities only include CancerDR [41], OAA [53], 
and SYFPEITHI [56], along with the NP libraries: AfroCancer [40], CancerHSP [42], CHMIS-C 
[43], InPACdb [49], MAPS [50], NPACT [7], and TIPdb [57].
2.2. Some recent success stories
Computational modeling has been applied to understand drug-target interactions in several 
validated anticancer drug targets, for the identification of novel inhibitors from small molecule 
databases and/or for the elucidation of modes of action. We here present some few recent 
cases. A typical example is the recent discovery of new inhibitors of CXC chemokine receptor 
2 (CXCR2) by applying ligand-based pharmacophore models [61]. It should be mentioned that 
CXCR2 and its ligand, CXCL8, are known to be implicated in a number of inflammation-medi-
ated diseases, including cancer [62–65]. In the study, Ha et al. generated a  pharmacophore 
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Database Description Web accessibility Reference
AfroCancer A data set of natural anticancer products 
from African flora
http://www.african-compounds.
org/about/afrocancer/
[40]
Cancer drug resistance 
database (CancerDR)
A database of 148 anticancer drugs and 
their effectiveness against around 1000 
cancer cell lines
http://crdd.osdd.net/raghava/
cancerdr/#thumb
[41]
CancerHSP An anticancer herbs database of systems 
pharmacology
http://lsp.nwsuaf.edu.cn/
CancerHSP.php/
[42]
ChEBI A database for chemical entities of 
biological interest
http://www.ebi.ac.uk/chebi/ [43]
ChEMBL An open large-scale bioactivity 
compound database
https://www.ebi.ac.uk/chembl/ [44]
CHMIS-C A herbal medicines database for cancer http://sw16.im.med.umich.edu/
chmis-c/
[45]
DrugBank A resource that combines detailed drug 
data with comprehensive drug target 
information
https://www.drugbank.ca/ [46]
DUDE datasets Benchmarking data sets of actives and 
decoys for diverse targets, including 
proteins, GPCRs and ion channels, 
clustered ligands, etc. drawn from ChEMBL
http://dude.docking.org/ [47]
EpiDBase A database for small molecule epigenetic 
modulators
http://www.epidbase.org/ [48]
InPACdb Indian plant anticancer compounds 
database
http://www.inpacdb.org/ [49]
MAPS Database A database of phytochemicals, including 
the data of >500 medicinal plants
http://www.mapsdatabase.com/ [50]
NANPDB A natural products database for 
compounds of Northern African origin, 
with a significant number of bioactive 
metabolites exhibiting anticancer activity
http://www.african-compounds.
org/nanpdb/
[51]
NCI Drug Information 
System (DIS)
A searchable database of 3D structures 
(mainly organic compounds) from the 
NCI Drug Information System (DIS)
https://cactus.nci.nih.gov/
ncidb2.2/
http://dtp.nci.nih.gov/docs/3d_
database/dis3d.html
[52]
NCI-DTP database Tested compounds from the National 
Cancer Institute (NCI) Developmental 
Therapeutics Program (DTP)
https://dtp.cancer.gov/databases_
tools/data_search.htm
[52]
NCI-FDA Several sets of FDA-approved anticancer 
drugs to enable cancer research
https://wiki.nci.nih.gov/display/
NCIDTPdata/Compound+Sets
[52]
NPACT A database for plant-based anticancer 
compounds
http://crdd.osdd.net/raghava/
npact/
[7]
Oral anticancer agents 
(OAA) from Singapore
A database of 39,772 oral anticancer 
agents prescribed to 8837 patients in 
Singapore, with 55 clinically significant 
drug-drug interactions for the evaluation 
of drug interaction facts
https://www.ncbi.nlm.nih.gov/
pubmed/22795926/
[53]
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model based on known CXCR2 antagonists and used it to screen a database of 5 million com-
mercially available compounds from different vendors. The authors were able to identify small 
molecule hits, which were further tested by in vitro screening in a cell-based CXCR2-mediated 
β-arrestin-2 recruitment assay, followed by several other cell-based assays. In vivo studies were 
conducted by lipopolysaccharide (LPS)-induced lung inflammation in mice. It was also shown 
that one of the compounds inhibits CXCR2 signaling through down regulation of surface 
CXCR2.
Moreover, the same compound was shown to inhibit CXCL8-mediated neutrophil migra-
tion and LPS-induced lung inflammation in mice significantly. The identified compounds 
were shown to also inhibit CXCR2/β-arrestin-2 association, cell migration and prolifera-
tion, and acute inflammation in mouse models. Another study combined structure-based 
docking and pharmacophores to design novel indole and chromene analogues, which were 
cyclin-dependent kinase 2 (CDK2) inhibitors. The identified compounds proved to be active 
against MCF-7 and HeLa cell lines. The study was conducted by exploiting stereo-specific 
information obtained from crystal structures of CDK2, substituting the pharmacophores on 
their moiety and docking the target protein to calculate the binding affinities [66]. Other 
recent successful cases, where docking, QSAR, machine learning, and pharmacophore-based 
screening were combined to search for small molecules targeting cancer, are abundant in the 
literature [67–70].
Database Description Web accessibility Reference
SANCDB A database of natural products from 
South Africa, containing also anticancer 
agents from the flora and fauna of this 
ecologically diverse country
https://sancdb.rubi.ru.ac.za/ [54]
SuperDrug A database of 3D-structures of active 
ingredients of essential marketed drugs
http://bioinf.charite.de/
superdrug/
[55]
SYFPEITHI A database of major histocompatibility 
complex (MHC) ligands and peptide 
motifs
http://www.syfpeithi.de/ [56]
TIPdb A database of anticancer, antiplatelet, and 
antituberculosis phytochemicals from 
indigenous plants in Taiwan
http://cwtung.kmu.edu.tw/tipdb/ [57]
p-ANAPL A collection of samples of natural 
products from African sources
http://www.african-compounds.
org/about/p-anapl/
[58]
PubChem A public repository for information on 
chemical substances and their biological 
activities
https://pubchem.ncbi.nlm.nih.
gov/
[59]
ZINC15 A free database of over 100 million 
purchasable compounds for virtual 
screening
http://zinc15.docking.org/ [60]
Table 1. Summary of some small molecule libraries currently available for anticancer drug discovery.
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3. Case study: structure-based virtual screening and QSAR studies on 
PRK1 inhibitors
3.1. Structure-based design studies (X-ray target structures and cross docking)
Four crystal structures of PRK1 are available in the protein data bank (PDB), Table 2. The PRK1 
binding site is reported to exhibit either intrinsic or induced flexibility [17, 24]. Moreover, dif-
ferent bound inhibitors are known to induce different conformational changes in the binding 
site residues [71]. Furthermore, chemical characteristics of the co-crystallized ligands play an 
important role in the applicability of the X-ray structure for virtual screening. Therefore, a 
cross-docking procedure was carried out, as a retrospective study aimed at determining the 
appropriate structure for the virtual screening. The selected structure should be able to bind 
the nonnative ligands with low root mean square deviation (RMSD), with respect to the refer-
ence binding conformation. On the other hand, the performance of the docking power and 
scoring functions is varying for different targets [32]. The docking power measures the ability 
of docking algorithms to predict the correct conformation of the ligands [72].
The four X-ray structures of PRK1, including the apo-form, were used for a cross-docking study 
[24]. The co-crystallized ligands were docked toward the target binding sites, using the Glide 
cross-docking script, implemented in Schrödinger Suite (2014 version) with standard precision 
(SP) for flexible ligand docking. In order to optimize the docking solution, an option was selected 
to perform post-docking minimization and includes number of poses up to 5 per ligand. The 
structures were prepared using the default setting implemented in Protein Preparation Wizard 
(Schrödinger 2014). The co-crystallized water molecules were deleted. Hydrogen atoms and 
partial charges were assigned. Finally, the structure energy minimized applying the OPLS 2005 
force field. The binding site was defined using Grid Generation of Schrödinger suite 2014 and sets 
the co-crystallized ligand as a center of the binding pocket. In the case of apo-structure 4OTD, 
the binding site was defined by applying centroid of selected residues Leu650 and Lys753 with 
box size 14 Å. A hydrogen bond constraint was defined at PRK1 hinge region reside Ser704. 
In addition, all ligands were prepared using LigPrep implemented in Schrödinger utility 2014 
involving generation of ionization and tautomeric states at pH 7.4 with less than 10 low-energy 
ring conformations. The ligands were energy minimized using MMFFs force field.
Ligand 4OTD 4OTG 4OTH 4OTI
RMSD SP RMSD SP RMSD SP RMSD SP
Lestaurtinib-4OTG 6.56 −4.29 0.24 −11.67 4.65 −7.82 7.56 −4.29
Ro-318220-4OTH 6.79 −7.01 2.98 −11.4 0.64 −11.76 6.47 −6.55
Tofacitinib-4OTI 3.14 −4.54 6.11 −8.09 2.7 −8.18 0.55 −8.8
Average RMSD 5.5 3.11 2.67 4.86
Table 2. RMSD values (Å) for the top-ranked docking solutions (using Glide SP as scoring function).
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The RMSD values were calculated, with respect to the respective reference ligand conforma-
tions. Table 2 shows the RMSD values and Glide SP scores for the top-ranked poses in the 
corresponding structures. It was observed that none of the available structures had a binding 
site conformation, which allowed all the three different ligands to be docked with RMSD 
< 2.0 Å. Furthermore, the calculated average RMSD values for each structure were high. 
However, the applied docking method performed well by reproducing the binding mode of 
the co-crystallized inhibitor in self-docking. Moreover, the docking method correctly scored 
the co-crystallized inhibitors at the top of the list (Table 2), e.g., the X-ray structure of the 
ligand lestaurtinib was re-docked with an RMSD = 0.24 Å into its co-crystallized structure 
(PDB: 4OTG), being also ranked as the top scoring pose (Glide SP = −11.67 kcal/mol). Similar 
results were observed with the other inhibitors when X-ray structures were docked toward 
their respective co-crystallized target structures. Meanwhile, the binding pocket conforma-
tion for the apo-form of PRK1 was not found to be suitable for docking when using any of the 
current inhibitor structures. RMSD values were high and the docking scores were low when 
compared with those obtained in the rest PRK1 structures (Table 2). Therefore, an ensemble 
of PRK1 structures was proposed for the further virtual screening study.
3.2. Docking of active inhibitors
The data set DS1 includes 28 active (Figures 1 and 2 [18]) and 300 inactive compounds. First, 
the active compounds were docked toward the ensemble of the three PRK1 structures using the 
previously described docking methods. The docking solutions were first inspected, with the aim 
of comparing them with the experimental conformations (the co-crystallized ligands in other 
kinases). The active compounds could be divided into four subsets, the first set being staurospo-
rine derivatives (10 actives, including the co-crystallized inhibitors lestaurtinib and Ro-318220). 
The second subset is made of the tofacitinib or pyrrolopyrimidine family (nine actives, in addi-
tion to the inhibitor tofacitinib in PDB ID: 4OTI). The third set was made of two isoquinoline 
derivatives, forming a group of five actives. The last subset contains the remaining inhibitors, 
with diverse scaffolds. The binding mode for each compound was analyzed and compared with 
the experimental data. As previously seen in the cross-docking for the co-crystallized inhibitors 
(Table 2), the binding modes for lestaurtinib and Ro-318220 were correctly reproduced. The 
binding modes for the further staurosporine derivatives were compared with these two ana-
logues. Since the ensemble docking procedure was applied to dock the actives, eight compounds 
were docked toward the 4OTG structure target site, while the others (Ro-318220 and BIM1) were 
docked toward the 4OTH site. It was interesting to notice that the top-ranked active poses had 
a quite conserved binding mode, which shares two H bonds, interacting with the hinge region 
of PRK1. The obtained binding modes for all staurosporine derivatives were identical to the 
published structure (in the PRK1 X-ray structure 4OTG). Since a part of the C-terminal regula-
tion region (C-tail) is not resolved, resulting in a more open and accessible ATP binding pocket, 
most of the staurosporine derivatives could be docked into it. Furthermore, all staurosporine 
derivatives were docked into both PRK1 structures, which are co-crystallized with one of stau-
rosporine derivatives (4OTG or 4OTH). For pyrrolopyrimidine and tofacitinib derivatives, the 
inhibitors were docked into three X-ray structures of PRK1. Tofacitinib was co-crystallized in 
the structure 4OTI. The RMSD value of re-docking tofacitinib was 0.55 Å. The binding modes 
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for the other analogues were compared with the experimental data (4OTI). Additionally, several 
other analogues were co-crystallized with the Akt1 kinase (PDB IDs: 3MV5, 3MVJ, and 3OCB).
Each active compound forms 2 H bonds with the hinge region, besides additional H bonds 
with the surrounding residues in the binding pocket. There are also some isoquinoline deriva-
tives that were co-crystallized with other kinases, e.g., cAMP-dependent kinase (PDB IDs: 
1YDS and 1YDR) and Rho kinase (PDB IDs: 2GNI). This subset of actives interacts with the 
PRK1 hinge region by mediating 1 H bond. A former virtual screening campaign had identi-
fied several actives, including CB-6046000 and CB-5743914, which were docked using the 
same previously described docking method. The binding mode showed two H bonds between 
the dihydroindol-2-one and the backbone of the hinge region, mainly Ser704 and Glu702. 
Furthermore, the binding mode of PD-0166285 matched the experimental data observed for 
the LCK kinase (PDB ID: 3KMM).
3.3. Scoring power
The rescoring for the derived docking poses was performed by calculating BFEs and using 
different solvation models implemented in the AMBER12 package. IC50 values had been pre-viously determined for 26 of the active compounds (Table 3), with only percentage inhibitions 
available for two others) [19]. Thus, the correlation coefficient (R2) between the experimental 
pIC50 and the calculated enthalpy changes (∆H) for protein-ligand binding was calculated 
(Table 3 and Figure 3). The BFE calculation was carried out using one snapshot after two 
consecutive minimizations steps and applying the Generalized Born solvation model [73, 
74]. First, the minimization was carried out for water and counterion molecules without the 
ligand-protein complex, which was restrained to their initial coordinates with a force con-
stant of 500 kcal/mol/Å2. In this step, there were 2000 iterations (beginning with 1000 steep-
est descent and followed by 1000 conjugate gradient). The second minimization step was 
applied for the whole system through 10,000 iterations (first 5000 steepest descent and then 
5000 conjugate gradients). A significant correlation was found when using the Nguyen and 
Simmerling (igb = 8) version of the Generalized Born solvation model [73, 74] and applying 
the two minimizations steps. The cross-validated R2 was found to be 0.60, with a root mean 
square error (RMSE) of 0.89. To understand the effect of the chemical modification on the 
main scaffold, the binding mode of the actives and the interactions in the binding pocket was 
analyzed. As mentioned previously, PRK1 actives can be divided into four subsets (Table 3). 
The docking score (Glide SP) and the MM/GBSA BFE values were employed to explore the 
differences in the inhibitory activity. However, there was a weak correlation between the 
pIC50 and Glide SP scores (R2 of 0.43, see Table 4).
It was observed, from docking, that the isoquinoline derivatives are able to form an H bond 
between the N atom of the isoquinoline motif and the NH backbone of Ser704 located in 
the hinge region. The isoquinoline motif occupied the adenine binding site; meanwhile, 
the substituents were located in the sugar-binding site, which is surrounded by several 
hydrophilic residues (e.g., Asp708, Asp750). Rescoring, using MMGBSA, showed that H-7 
(IC50 = 658 μM and ∆H = −34.51 kcal/mol) had a higher score than HA-1077 (IC50 = 1.95 μM and ∆H= −29.42 kcal/mol), Table 3. The more favorable value resulted from the additional 
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Compound IC
50
 (nM) Exp. pIC
50
Target 
structure
Glide SP MM/GBSA** PEOE_PC- Pred. pIC
50
*
Ro-318220 78.3 7.11 4OTH −11.36 −45.97 −2.71 7.16
BIM1 579 6.24 4OTH −9.82 −46.10 −2.29 6.58
PKC-412 14.2 7.85 4OTG −10.98 −55.52 −3.26 8.26
Lestaurtinib 8.6 8.07 4OTG −11.43 −46.92 −2.77 7.30
K252a 3.2 8.49 4OTG −11.38 −51.40 −2.95 7.80
Staurosporine 0.81 9.10 4OTG −11.83 −60.86 −2.72 8.59
Calbiochem681640 1441 5.84 4OTG −10.61 −47.90 −1.96 6.71
BIM 154.2 6.81 4OTG −9.16 −38.70 −1.96 5.58
K252c 4OTG −10.53 −40.12
Quercetin 4OTG −8.43 −48.23
CP-690550 
(tofacitinib)
129 6.89 4OTI −8.81 −38.88 −2.01 5.55
Z1139203558 55730 4.25 4OTG −8.52 −27.91 −1.84 4.41
Z1129905037 53380 4.27 4OTI −9.61 −35.25 −1.82 5.29
CB-38374289 42560 4.37 4OTI −10.49 −33.36 −2.11 5.49
CB-85384930 34020 4.47 4OTH −9.04 −35.48 −1.48 4.98
Z1139202903 31470 4.50 4OTI −9.37 −37.77 −2.09 5.62
Z991906728 26400 4.58 4OTG −9.18 −28.92 −2.02 4.75
CB-76536004 13090 4.88 4OTG −9.43 −33.02 −1.45 4.83
Z1039084878 6210 5.21 4OTG −8.76 −29.13 −2.10 4.73
PZ0151 1060 5.97 4OTI −8.54 −43.19 −2.16 5.97
H-7 658.5 6.18 4OTH −8.68 −34.51 −1.43 4.78
HA-1077 1945 5.71 4OTI −8.71 −29.42 −1.39 4.31
F2457-0067 70300 4.15 4OTH −8.49 −36.31 −1.76 5.10
F2458-0011 53730 4.27 4OTI −8.07 −29.18 −1.70 4.34
Ambnee93542761 29330 4.53 4OTH −9.12 −30.33 −1.68 4.66
CB-6046000 5350 5.27 4OTG −7.39 −47.01 −1.57 5.70
CB-5743914 2940 5.53 4OTG −9.89 −41.07 −1.72 5.81
PD-0166285 5517 5.26 4OTG −7.48 −39.17 −2.41 5.53
Comparison of experimental pIC50 versus predicted pIC50 values calculated by QSAR_3 for the 26 training set 
molecules [18].
The BFE values were calculated according to the docked structure (target structure), which are supplied with the 
PDB ID.
Table 3. Biological activity, calculated BFE and docking scores of the active compounds.
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hydrophobic interactions between the front hydrophobic pocket residues and Phe910 (from 
the C-tail) and the methyl substituent on the piperazine ring. Meanwhile, the van der Waals 
interaction became weaker in the case of HA-1077. This could be explained by the shifting 
of the position of the substituent, since its seven-membered ring is bulkier. Both derivatives 
contain a positively charged ring nitrogen, which consequently forms an additional H bond 
in the ATP-sugar binding pocket (Figure 4). Meanwhile, the interaction between Asp708 
and the piperazine ring enables the methyl group to get closer to Phe910 and its surround-
ing residues. Moreover, the sulfonyl moiety of both compounds is located under the P-loop, 
where it forms hydrophilic and hydrophobic interactions.
Figure 3. Correlation curve of pIC50 versus ∆H scores of actives using MM/GBSA.
GLIDE ∆H
SP XP GB8
R2 0.43 0.27 0.65
EF1% 100 100 25
EF3% 30.3 33.33 9.1
AUC* 0.90 0.88 0.66
*AUC = area under the ROC curve.
Table 4. Enrichment study results using an ensemble of PRK1 structures, where the available scoring functions in 
Schrödinger and BFE methods were considered. Where SP: Standard Precision; XP: Extra Precision and ∆H: enthalpy 
score; GB8: Generalized Born theory model.
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The remaining compounds share common interactions (as previously mentioned), but the 
biological activities of these compounds could not be predicted using the derived BFE model. 
However, the lower activity of compound ambnee93542761 could be explained by the loss 
of the interaction between of the sulfonyl moiety and weak hydrophobic interactions with 
Phe910. Nonetheless, it forms a hydrogen bond with the catalytic Asp764 (IC50 = 29.33 μM and ∆H = −30.32 kcal/mol). The results of this subset show the importance of the hydrophobic 
interactions with the Phe910 of the C-tail and its surrounding residues. However, the BFE 
values and docking scores failed to predict the affinity of F2457-0067, which shows a favor-
able BFE value but a low IC50 value (Table 3). This could probably result from the long linker between the isoquinoline motif and the positively charged morpholine ring. The generated 
conformations show additional van der Waals interactions. On the other hand, the morpho-
line ring shows more polar properties compared to the other compounds.
The second subset of actives is made of staurosporine derivatives. Most of these compounds 
form two H bonds between the pyrrole ring and the hinge backbone (NH of Ser704 and CO 
of Glu702). The docking results for staurosporine derivatives were compared with two PRK1 
crystal structures (4OTG and 4OTH). The favorable BFE values of staurosporine derivatives 
could be attributed to the strong hydrophobic interactions with residues from the P-loop, 
e.g., Val635 and Leu627, in addition to the interactions with Leu753. The only observed 
deviation was with parts of the docked ligand interacting with the sugar pocket, e.g., stau-
rosporine (the most active compound) showed a BFE value of ∆H = −60.85 kcal/mol and an 
IC50 = 0.0008 μM (Table 3). The favorable BFE value and activity of staurosporine could be estimated through the targeting of both hydrophobic pocket residues (behind the gatekeeper 
Met701 and near Phe910); on the other hand, several polar groups occupied the sugar polar 
Figure 4. Comparison between the docking poses of two isoquinoline derivatives H-7 (magenta) and HA-1077 shown as 
green sticks (PRK1 PDB code: 4OTH). The figure was designed using MOE.
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pocket. By comparison with lestaurtinib (IC50 = 0.0086 μM and ∆H= −46.92 kcal/mol), the dif-ferences in the activity and BFE values could be attributed to the smaller ring/shorter linker 
in lestaurtinib for targeting Asp708 and Asp750 (Figure 5).
The third subset of PRK1 inhibitors is made of tofacitinib analogues. Ten compounds belong 
to this subset (Table 3). All derivatives interact with the hinge region by forming two H bonds 
through the pyrrolopyrimidine scaffold (Figure 6). The major substituents, which influence 
notably the BFE values and the biological activity of tofacitinib, are the N-methyl of the pyridine 
ring. Any chemical modification changing these interactions will consequently change the BFE 
value and the activity. A comparison of the calculated BFE values of tofacitinib with those of 
the other derivatives could clarify the effects of these interactions. As previously mentioned, the 
loss of the interactions made with the P-loop residues clearly influences the calculated BFE val-
ues and, therefore, affects the biological activities. Consequently, Z1129905037 (IC50 = 55.73 μM and ∆H = −27.92 kcal/mol) possesses a BFE value lower than tofacitinib (IC50 = 0.129 μM and ∆H = −38.88 kcal/mol) (Table 3). Furthermore, contrary to tofacitinib, the binding mode of 
Z1129905037 does not show hydrophobic interactions with the residue located at the bottom 
of the binding pocket. The ATP-sugar binding site is occupied by non-polar substituents in the 
case of Z1129905037, which is unfavorable and consequently reduces the activity. The other 
tofacitinib analogues, which do not contain any tertiary amine as the linker, show higher BFE 
values and obviously lower biological activities. One exception is PZ0151 (IC50 = 1.06 μM and ∆H= −43.19 kcal/mol) which displays the same binding mode with tofacitinib. The pyrrolidine 
Figure 5. Comparison between the docking pose of staurosporine (seen in cyan sticks) and the binding mode of 
lestaurtinib (shown in white brown sticks) at PRK1 structure 4OTG. The figure was designed using MOE.
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ring in PZ0151 takes the position of the CN group of tofacitinib but rather shows a lower activ-
ity. This could be as a result of the small size of the binding site under the P-loop residues, which 
is not suitable for large substituents. In general, it is difficult to explain the changes of the BFE 
values caused by chemical modification of all compounds under study. The observed correla-
tion coefficient (R2 = 0.65) could only be used to explain major differences in biological activities. 
However, it could be used as an indicator to identify the interactions, which play major roles in 
the determination of biological activity.
3.4. Ranking power
An enrichment study was performed in order to measure the ability to identify known bind-
ers or actives in large databases of inactives. The previously mentioned data set (named 
DS1), containing 28 actives and 300 inactives, was used to perform the enrichment study. The 
ligands were docked using the same ensemble and rescored depending on the previous find-
ings. The results are presented in a BOX-PLOT and receiver operating characteristic (ROC) 
curves (Figures 7 and 8). Table 4 shows enrichment study results, using an ensemble of PRK1 
structures, where the available scoring functions in Schrödinger and BFE methods were con-
sidered (∆H, Glide SP and Glide XP). As seen in Figure 7, Glide SP was able to discriminate 
between actives and inactives better than the BFE scoring (∆H).
The median values of the pair active/inactive were −9.17/7.23 and −38.79/34.02 for Glide SP 
and ∆H, respectively. The area under the curve (AUC) and enrichment factors (EF) at two dif-
ferent percentages were calculated. Table 4 shows the enrichment study results. It is interest-
ing to note that at EF1%, all screened hits were actives when using both Schrödinger’s scoring 
functions (Glide SP and XP). Interesting, it was also observed that for the EF3% (for Glide SP 
and XP), the rate of true positives was 100% (Table 4). The main factor to measure the ranking 
Figure 6. Comparison of the docking pose of Z1129905037 (shown as cyan sticks) and the binding mode of tofacitinib 
seen in magenta, at the binding site of PRK1 structure 4OTI. The figure was designed using MOE.
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power of the applied docking methods was the AUC value (Table 4). It is clear that the Glide 
scoring functions performed better to discriminate between the actives of inactives, having 
AUC = 0.90 and 0.88 for SP and XP, respectively.
3.5. QSAR model generation
Several QSAR models were generated to identify a possible correlation between experimen-
tally obtained pIC50 values and calculated BFE or descriptor values (for the compounds on 
Figures 1 and 2). Calculated BFE (obtained by the MM/GBSA approach) from the previous 
study and 2D molecular descriptors, e.g., different descriptors referring to the partial charge 
and number of rotatable bonds, were considered. Since the Glide SP score showed a signifi-
cant discrimination power between the active and inactive compounds, further scoring func-
tions were also tested to optimize the QSAR models.
Figure 7. Box plots for the active and inactive compounds using the respective score values.
Figure 8. Enrichment plot showing comparison of the % actives found at a given percentage of the ranked database for 
DS1, using GLIDE SP, XP, and ∆H (MMGBSA).
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The best correlation coefficient in the previous study was found by applying Nguyen and 
Simmerling (igb = 8) Generalized Born solvation model [73, 74], after a minimization step 
(R2 = 0.65, RMSE = 0.89 and cross-validated q2 = 0.60, n = 26). In order to improve the correla-
tion, partial charges of the ligands were calculated to compute several molecular descrip-
tors for generating PLS models [75]. The inclusion of the PEOE_VSA-0 descriptor improved 
the correlation coefficient value only slightly (model QSAR_, R2 = 0.68, RMSE = 0.8, and q2 
= 0.61, n = 26). This descriptor indicates the partial equalization of electronegativities with 
approximated accessible van der Waals surface area (in Å2) of the molecule [76]. Furthermore, 
the inclusion of another descriptor based on ligand partial charges (PEOE_PC-) [76], which 
indicates to the total negative partial charge, was used instead of PEOE_VSA-0 to generate 
QSAR_2 (R2 = 0.70, RMSE = 0.78 and q2 = 0.62, n = 26; Eq. (1)). The model QSAR_3, containing 
three descriptors, showed a slightly better correlation coefficient (R2 = 0.71, RMSE = 0.76 and 
q2 = 0.63, n = 26; Eq. (2)). The relative importance of the individual descriptors was MM-GBSA: 
1, GLIDE_SP: 0.417, and PEOE_PC-: 0.371. The other tested descriptors were not helpful and 
were not considered for the final models.
Further internal validation of the generated QSAR models was carried out by means of boot-
strapping, in which the samples are randomly selected from the used inhibitors to form train-
ing and test sets [77, 78]. The respective models are generated, and their statistical parameters 
(R2 and q2) are calculated and compared with those of the original QSAR models (which had 
been generated from the whole data set). The random selection of the samples was performed 
within each cluster generated by hierarchical clustering, depending on the structural similar-
ity or within activity distribution clusters of PRK1 inhibitors (low, moderate, and high active 
inhibitors) [77]. PRK1 inhibitors can be divided into four subsets depending on the chemical 
scaffolds (Figures 1 and 2). In the next step, hierarchical clustering using maximum com-
mon substructure (MACCS) keys and calculation of Tanimoto coefficients were carried out 
using the molecular operator environment (MOE) software tool (chemical computing group, 
Montreal, Canada, version 2014). Then, several samples within each cluster were taken, 
considering their activities. From 26 compounds, the sample subset contains only 20 inhibi-
tors. The statistic parameters of the obtained QSAR models are presented in Table 5. The 
goal of the bootstrapping is to perturb the training set while not considering the statistical 
parameters of the test set. Since the obtained QSAR models were built from subset of the total 
data set, the values of  R BT 2 and  q BT 2 satisfy the minimum acceptable statistical parameters when 
Training set (20 inhibitors) Test set (6 inhibitors)
R2 RMSE q2
 R 
BT
 
2
 RMSEpred  q 
pred
 
2
 
QSAR_BT_1 0.71 0.73 0.65 0.43 1.11 0.06
QSAR_BT_2 0.72 0.72 0.63 0.58 0.95 0.19
QSAR_BT_3 0.72 0.71 0.60 0.67 0.84 0.28
Table 5. Statistical parameters of obtained QSAR models in bootstrap validation.
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 compared with the three original QSAR models. These values also revolve around the values 
of the original QSAR models, generated from 26 PRK1 inhibitors (Table 5). It was observed 
that the obtained QSAR models possess acceptable statistic parameters (q2 > 0.5) and were 
comparable with those found in the original QSAR models. However, the QSAR_BT_3 model 
showed poor correlation when compared with the results found in the whole data set (q2 = 
0.60, Table 5). The remaining six inhibitors were used as the external test set to verify the abil-
ity of the obtained QSAR models (QSAR_BTs) to predict the biological activities of the test 
set compounds. The values of  R 
pred
 2 between the calculated and measured pIC50 are 0.43, 0.58, and 0.67 for QSAR_BT_1, QSAR_BT_2, and QSAR_BT_3, respectively (Table 5). These results 
may confirm the ability of the model QSAR_3 and its derivatives (QSAR_BT_3) to predict the 
biological activities of novel compounds.
Interestingly, QSAR_3 have predicted pIC50 values higher or close to 7 for the most potent PRK1 inhibitors (IC50 < 100 nM). Moreover, QSAR_3 possessed the ability to distinguish between weak, moderate, and highly potent compounds (Table 3). Thus, the model could 
be used as a filter for the prioritization of specific compounds (hits) for synthesis and test-
ing. Figure 9 displays the graph of the correlation between the observed and predicted pIC50 values using QSAR_3 model.
3.6. Validation of the generated QSAR models and GSK databases screening
It has previously been demonstrated that considering only the statistic parameters (R2, RMSE, 
and q2) to validate QSAR models is insufficient and sometimes misleading [78–82]. Therefore, 
it is important to validate QSAR models by testing the ability to accurately predict the biologi-
cal activities of ligands not used for QSAR model generation. In the current study, two data 
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Figure 9. Correlation plot of the observed versus predicted pIC50 values of the training set (n = 26) using QSAR_3 model.
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sets of compounds were available: the first set containing 26 PRK1 inhibitors with IC50 values was used as a training set for QSAR model generation (Figures 1 and 2). The second set was 
used as an external test set to validate the QSAR model. These compounds were identified 
from an in vitro screening (GSK PKIS1) and contain 35 compounds including 14 active com-
pounds and 21 inactive compounds (Figures 10 and 11) [18]. Seven of the active compounds, 
for which IC50 values were measured (0.04–4.9 μM, Table 6), were taken as external test set to further evaluate the predictive power of the QSAR models.
Table 5 provides a comparison of the calculated pIC50 versus experimental pIC50 values. The calculation of pIC50 values was performed by using the QSAR_1, 2, and 3 models. An impor-tant statistic parameter to test the predictive power of the QSAR models is the correlation coef-
ficient  R 
pred
 2 between the predicted and observed pIC50 values for the test set [82]. The correlation coefficients between the experimental and predicted pIC50 values for the seven test set com-pounds were quite weak ( R 
pred
 2 = 0.49, n = 7) when using QSAR_3 model. The predictive power 
of the QSAR_1 and 2 models was investigated. The correlations of both models were within a 
similar range ( R 
pred
 2 = 0.58 and 0.37, n = 7). A further analysis was performed to detect the outli-
ers depending on Z-score values. The Z-score values were calculated using MOE, for QSAR_3. 
Golbraikh et al. mentioned that at least five compounds are required for a test set to validate 
a QSAR model [80]. After the analysis of the correlation and Z-scores, compound SB-750140 
found to negatively affect the correlation coefficients. The correlation using QSAR_3 shows 
an improvement ( R 
pred
 2 = 0.95, RMSD = 0.17 and q2 = 0.89, n = 6). A similar observation was 
made for the two other QSAR models (QSAR_1:  R 
pred
 2 = 0.93, RMSD = 0.21 and q2 = 0.82, n = 6; 
QSAR_2: R 
pred
 2  = 0.98, RMSD = 0.12 and q2 = 0.95, n = 6). The outcomes confirm that the  generated 
Figure 10. Chemical structures of PRK1 14 actives identified from screening the GSK PKIS1 [18].
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Figure 11. Chemical structures of PRK1 14 actives identified from screening the GSK PKIS1 (continued) [18].
Compound Binding
1 μM
IC
50
nM
pIC
50
Pred. pIC
50
QSAR_3
Pred.pIC
50
QSAR_1
Pred. pIC
50
QSAR_2
GSK943949A Yes 40 7.40 7.33 7.79 7.99
GSK614526A Yes 68.1 7.17 7.09 7.68 7.69
SB-750140 Yes 120 6.92 5.70 6.06 5.88
GSK619487A Yes 181.3 6.74 7.11 7.62 7.65
GSK554170A Yes 710 6.15 6.34 6.76 7.02
GSK938890A Yes 3600 5.44 5.67 5.77 6.49
SB-358518 Yes 4900 5.31 5.84 6.16 6.24
GW811761X Yes No IC50 5.72 5.97 6.05
GW784307A Yes No IC50 6.86 7.03 7.36
GSK1007102B Yes No IC50 6.34 6.72 7.21
GSK561866B Yes No IC50 5.82 6.10 6.45
GSK319347A Weak No IC50 6.77 6.26 6.96
GW759710A Weak No IC50 4.99 5.26 5.41
GW829877X Weak No IC50 5.26 5.52 5.53
GSK1030059A No 7.66 8.08 7.98
GSK625137A No 4.16 4.43 4.47
GW290597X No 6.52 5.67 6.53
GW513184X No 5.27 5.25 5.55
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QSAR models show satisfactory ability to predict the biological activities of the test set com-
pounds. Thus, they could be accepted having an  R 
pred
 2 value > 0.5 [82]. Moreover, taking the last 
 consideration of the threshold for the predicted pIC50 > 7 found in case of actives to refer to potent compounds was clearly in the test set, since the most potent inhibitors in the test set 
(IC50 < 100) were identified with predicted pIC50 > 7 (Table 6). Meanwhile, the biological activi-ties of the moderately active compounds were predictive with calculated pIC50 in the range 5.5–7 (Table 6). Among the inactive compounds in the test set, three compounds were pre-
dicted to be highly potent compounds, but these compounds were inactive in the assay. The 
visualization of the false positives could not clarify the absence of activity of both compounds. 
However, GSK978744A and GSK1030059A, which mainly target the PLK kinase, possess the 
same chemical scaffold, and their binding modes were investigated and compared with the 
binding modes of analogues co-crystallized with other kinases (CDK2; PDB ID: 2I40, NEK2; 
PDB ID: 2XNN). However, it is not clear, from structural interactions, why this compound is 
not active. Additionally, it might possible that the exclusion of entropy changes or solvation of 
the binding pocket could play a role in the wrong estimation of the biological activity.
Since the QSAR_2 model shows high value of  R 
pred
 2 in the test set (QSAR_2:  R 
pred
 2 = 0.98, RMSD = 0.12 
and q2 = 0.95, n = 6), the discrimination performance was therefore discussed. Similar to QSAR_3, 
the most potent inhibitors in the test set (IC50 < 100) were identified with predicted pIC50 > 7 
Compound Binding
1 μM
IC
50
nM
pIC
50
Pred. pIC
50
QSAR_3
Pred.pIC
50
QSAR_1
Pred. pIC
50
QSAR_2
GW643971X No 5.27 5.19 5.60
GW794607X No 5.44 5.66 5.71
SB-409514 No 5.13 5.56 5.48
GSK994854A No 5.93 5.90 6.50
GW874091X No 5.26 5.65 5.56
GW693481X No 3.25 3.80 3.92
GSK1000163A No 6.21 7.02 6.91
GSK1220512A No 6.03 5.51 6.58
GSK317314A No 5.94 6.64 6.48
GSK579289A No 5.14 4.89 5.60
GSK949675A No 7.20 7.99 7.89
GW580496A No 6.18 5.37 6.77
SB-476429-A No 4.68 4.67 4.92
SB-744941 No 4.73 5.52 5.22
GSK571989A No 6.26 6.42 6.75
GW779439X No 4.83 4.76 5.35
GSK978744A No 7.76 7.75 8.10
Table 6. Comparison of the experimental pIC50 versus the calculated pIC50, using the generated models QSAR_1, 2 and 3 [18].
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(Table 6). Furthermore, between the remaining active compounds, two of them were predicted 
to be high potent inhibitors pIC50 > 7 (GW784307A: predicted pIC50 = 7.36; GSK1007102B: predicted pIC50 = 7.21). However, the IC50 values of these two compounds have not been measured yet, but it reported to be active since it binds to PRK1 at 1 μM. Thus, the consideration of the threshold 
for the predicted pIC50 > 7 could also be applicable in the QSAR_2 model. The weak active com-pounds GSK319347A, GW759710A, and GW829877X (shown in Table 6) also predicted as moder-
ate or low active compounds where predicted pIC50 values were less than 7. Among the inactive compounds, three compounds (the same compounds as in the case of the QSAR_3 model) were 
predicted to be highly potent compounds, but these compounds were inactive in the assay.
  
QSAR _ 2 :  pIC 50  = 0.15509 − 0.09778
   * PEOE_PC - –0.09778 * MM-GBSA 
 ( R 2  = 0.70, RMSE = 0.78  q 2  = 0.62,  n = 26 ) 
 (1)
  
QSAR _ 3 :  pIC 50  = –1.37129–0.56938 * PEOE_PC-
    –0.08688 * MM-GBSA–0.26312 * GLIDE_SP     
 ( R 2  = 0.71,  RMSE = 0.76 and   q 2  = 0.63, n = 26 )  
 (2)
By comparing the three generated QSAR models (QSAR_1, 2, and 3) depending on the pre-
dicted pIC50 values among them to the measured ones, it was found the predicted pIC50 values when using QSAR_3 model were closer to the experimental values (Table 6), but QSAR_2 
model showed the highest value of  R 
pred
 2 in the test set. Furthermore, in bootstrap validation, it 
was found that the QSAR_3 model had the ability to predict the biological activity of the test 
set compounds more accurately than the models QSAR_1 and 2 (Table 6). Thus, the QSAR_3 
model could be used to predict the biological activities of the highly potent compounds, 
which should exhibit biological activities power in the nanomolar range and differentiate 
between the active compounds, according to their activity (low, moderate, and high).
3.7. Virtual screening using the p-ANAPL library
The above protocol was further used to virtually screen for possible PRK1 inhibitors from the 
p-ANAPL library [58]. As previously applied, ensemble docking was performed to dock the 
compounds to the X-ray structures of PRK1 stored in the PDB. Both data sets were prepared 
using Schrödinger 2014.U2, including the generation of several conformations per compound. 
The docking solutions were visualized using MOE to explore the conserved interactions with 
residues at the PRK1 hinge region. The selection of the hits was based first on the displayed 
binding mode, followed by their scoring, then predicting the pIC50 values using the generated QSAR models. Depending only on docking scores was insignificant for the selection of prom-
ising hit compounds. The docking solutions for the entire data set were visualized and several 
hits compounds were selected. In the next step, their predicted pIC50 values were calculated using QSAR_1, 2, and 3. Depending on the set threshold for the predicted pIC50, several top scoring compounds could be selected as promising hits for the biological assays, e.g., those in 
Figure 12. Figure 13 displays the binding modes of the selected hits and the interaction with 
residues at the binding pocket of the corresponding X-ray structure of PRK1.
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One of the promising hits, DBT-6b, is Bartericin B (MW = 408.49; PubChem CID: 12136210) 
from Dorstenia barteri [83]. The binding mode of DBT-6b is shown in Figure 13A. The 
compound is predicted to interact with hinge region residue Ser704 with one H bond. 
The phenol ring forms an additional H bond with the backbone of Asp764 from the DFG-
motif. The interaction with the front polar pocket and the ribose binding pocket is medi-
ated by two H bonds between Asp708 and propanol substituent in DBT-6b. The calculated 
pIC50 values were 7.85, 7.64, and 7.45 using the generated QSAR models QSAR_1, 2, and 3, respectively. The second hit (P87), vitexin or apigenin-8-C glucoside (MW = 432.38; 
PubChem CID: 5280441), is a flavonoid glycoside from diverse sources, e.g., Hyparrhenia 
hirta [84]. The binding mode of P87 (Figure 13B) shows that the compound might form 
one H bond with the hinge region residue Ser704. Additionally, the substituents on the 
Figure 12. Chemical structures of the selected hits.
Figure 13. Docking poses of the selected hits in PRK1 binding pocket. (A) Docking poses of DBT-6b in the binding pocket 
of PRK1 structure 4OTG. (B) Docking pose of P87 in PRK1 structure 4OTH. The figure was designed using MOE.
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oxane ring are targeting the front polar pocket and forming two H bonds with Asp708 
and Asp750. The phenyl ring interacts with the back hydrophobic pocket and further 
forms an H bond with Asp764 in the DFG motif. P87 was predicted to be a highly potent 
compound, with a predicted pIC50 value greater than 7, using QSAR models (pred_pIC50= 8.02, 8.6, and 9, respectively). Bartericin B and vitexin are the only two examples of prom-
ising compounds from natural products which could target PRK1. Among the screened 
databases, other hits were selected as promising compounds, which could inhibit PRK1 
activity in the nanomolar range. In further investigations, the selected compounds can be 
submitted for biological assay to figure out their ability to bind into PRK1.
4. Conclusions
This chapter provides a brief summary of database resources for anticancer drug discovery 
and some recent inputs and success stories for the identification novel inhibitors of selected 
anticancer drug targets by the use of computer modeling. While the experimental valida-
tion of some of the natural product hits identified in the case study is ongoing, the question 
about the applicability domains of the derived QSAR models reported is still to be answered. 
Among the identified hits, 50 closely similar compounds to Bartericin B (with cut-off Tanimoto 
coefficient of 0.7), having reported biological activities in PubChem [59] and ChEMBL [44], 
with 239 biological activities and 152 published patent data. A similarity search of vitexin in 
PubChem gives 112 similar compounds, corresponding to 524 biological activities and 208 
patents. Bartericin B is known to exhibit antimicrobial activities against Trichomonas gallina-
rum, with minimum lethal concentrations (MLCs) of 0.244 and 0.121 μg/mL after 24 H and 
48 H, respectively [83], while its analogue (Bartericin A from Dorstenia angusticornis) is known 
to be very active against some bacteria and yeasts associated with human pathologies [85]. 
Both chalcones are known to also have potential antiprotozoal activities [86], e.g., against 
Plasmodium falciparum [87]. Vitexin, on the other hand, is known for its antioxidative and [88] 
spasmolytic effects [89]. The compound is known to be abundant in plants of the genus Vitex 
(Verbenaceae), which is known to exert insect antifeeding activities, among others [90]. These 
compounds could now be tested in biological assays for potential PRK1 inhibition.
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